HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The novel Kv1.5 channel blocker vernakalant for successful treatment of new-onset atrial fibrillation in a critically ill abdominal surgical patient.

AuthorsP Friederich, H Pfizenmayer
JournalBritish journal of anaesthesia (Br J Anaesth) Vol. 107 Issue 4 Pg. 644-5 (Oct 2011) ISSN: 1471-6771 [Electronic] England
PMID21903653 (Publication Type: Case Reports, Letter)
Chemical References
  • Anisoles
  • KCNA5 protein, human
  • Kv1.5 Potassium Channel
  • Pyrrolidines
  • vernakalant
Topics
  • Abdomen (surgery)
  • Aged
  • Anisoles (therapeutic use)
  • Atrial Fibrillation (drug therapy, etiology)
  • Critical Illness
  • Female
  • Heart Rate (drug effects)
  • Humans
  • Ileus (surgery)
  • Kv1.5 Potassium Channel (antagonists & inhibitors)
  • Laparotomy
  • Postoperative Complications (drug therapy)
  • Pyrrolidines (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: